What is Schizophrenia?
Schizophrenia is a severe mental illness, which interferes with a person’s ability to think, manage emotions, make decisions, and relate to others.
Although Schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early twenties for men and the late twenties to early thirties for women. It is uncommon for the disease to be diagnosed younger than 12 or older than 40.
Schizophrenia is not caused by just one genetic variation but a complex interplay of genetics and environmental influences. While Schizophrenia occurs in one percent of the general population, having a history of family psychosis significantly increases the risk.
Schizophrenia infographic occurs in roughly 10% of people who have a first-degree relative with the disorder, such as a parent or sibling.
What is Schizophrenia Market Size?
The market size of Schizophrenia in 7MM in 2017 was USD 6,066.97 million
What are the Schizophrenia Emerging Drugs?
The emerging drugs of the Schizophrenia market are
Doria (risperidone ISM)
Roluperidone (MIN-101)
SEP-363856
Pimavanserin
Encenicline (EVP-6124
Dexmedetomidine (BXCL501)
Avisetron (AVN-211)
ALKS 3831 (Olanzapine + Samidorphan)
AVP-786
Lu AF11167
GWP42003 (Cannabidiol/GWP42003-P)
BI 409306
KarXT
TAK-831
NaBen (Sodium Benzoate)
BI 425809
BIIB104 (AMPA)
PF-06412562
CTP-692
Evenamide (NW-3509/NW-3509A)
Miricorilant
MK-8189
CPL500036
And many others
About Athletes Foot Market
The athlete's foot, also known as Tinea pedis, is a cutaneous fungal infection caused by a dermatophyte infection. It is characterized by itching, flaking, and fissuring of the skin. It may manifest in three ways: the skin between the toes may appear macerated (white) and soggy; the soles of the feet may become dry and scaly; the skin all over the foot may become red, and vesicular eruptions may appear.
Three groups of fungal pathogens, referred to as dermatophytes, have been shown to cause tinea pedis: Trichophyton sp, Epidermophyton sp, and Microsporum sp. The disease manifests as a pruritic, erythematous, scaly eruption on foot and depending on its location, three variants have been described: interdigital type, moccasin type, and vesiculobullous type.
Tinea pedis infections are typically easy to distinguish and diagnose.
However, moccasin athlete's foot a comprehensive view complete identification of the causative fungi should be established to confirm a diagnosis and ensure proper treatment. Diagnosis of tinea pedis is based on history and clinical appearance of the feet in addition to direct microscopy of a potassium hydroxide (KOH) preparation.
Cultures or histological examinations are rarely required. A Wood's lamp is not usually helpful in diagnosing tinea pedis but can be used to rule out other diagnoses like infection with Malassezia furfur or erythrasma—Malassezia furfur and Corynebacterium minutissimum both fluoresce under ultraviolet light while other common dermatophytes do not.
DelveInsight’s ‘Athletes foot Market Insights, Epidemiology and Market Forecast-2030’ report delivers an in-depth understanding of the Athlete’s foot, historical and forecasted epidemiology as well as the Athlete’s foot market trends in the United States.
About Car T cell Therapy for Multiple Myeloma Market
A cure for Multiple Myeloma currently doesn’t exist. However, significant research is making progressive leaps toward a treatment that eliminates the cancer entirely. None of the CAR T-cell therapies gained approval for Myeloma, however some of the late-stage potential therapies will impact the market in the near future.
Recent advancement in the upcoming therapies for Myeloma treatment with the development of CAR-T therapies will allow for greater availability of these approaches to patients. A number of new approaches are being explored to better optimize cellular therapies in myeloma.
Combinations with immunomodulatory drugs and checkpoint inhibitors may continue to enhance CAR T-cell activity, and clinical trials of these combinations are underway. The global Multiple Myeloma market is likely to be driven by the shift in the lifestyle of consumers and growing cases of plasma cancer across the globe.
The rising penetration of cancer drugs including potential CAR-T therapies with their upcoming launch is expected to bode well for the growth of the global Multiple Myeloma market.
Chimeric antigen receptor (CAR) T-cell therapy involves genetic modification of patient’s autologous T-cells to express a CAR, specific for a tumor antigen, followed by ex vivo cell expansion and re-infusion back to the patient. CAR T-cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signalling domains.
A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signalling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137 (Morgenstern & Irwin, 2019).
T-cell genetic modification may occur either via viral-based gene transfer methods or non-viral methods, such as DNA-based transposons, CRISPR/Cas9 technology, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), or direct transfer of in vitro transcribed-mRNA by electroporation.
Multiple myeloma is a malignant proliferative disease of plasma cells. Clonal plasma cells producing immunoglobulin, proliferate and accumulate abnormally within the bone marrow, leading to hematopoietic insufficiency and lytic bone lesions. According to WHO, in 2018, 159,985 incident cases of multiple myeloma were reported in the world.
Though some substantial improvement measures have been implemented in the therapy of multiple myeloma, this disease still remains a highly incurable fatal hematopoietic malignancy for which potentially curative and safer novel treatments are required.
DelveInsight’s ‘CAR T-Cell Therapy for Multiple Myeloma Market Insights and Market Forecast-2030’ report delivers an in-depth understanding of the CAR T-Cell Therapy use for Multiple Myeloma as well as the CAR T-Cell Therapy market trends for Multiple Myeloma in the 6MM i.e., United States and EU5 (Germany, Spain, Italy, France and the United Kingdom).
The Multiple Myeloma CAR T-Cell Therapy market report provides current treatment practices, emerging drugs, CAR T-Cell Therapy market share of the various CAR T-Cell Therapies for Multiple Myeloma, the individual therapies, current and forecasted Multiple Myeloma CAR T-Cell Therapy market Size from 2017 to 2030 segmented by seven major markets.
The Report also covers current Multiple Myeloma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Comments